ORYZON announces FDA approval of IND for PORTICO, a Phase IIb trial with vafidemstat in Borderline Personality Disorder
Recruitment ongoing in EuropePrimary objectives: to assess the effect of vafidemstat to address agitation and aggression and to improve overall...